| Gavin Giovannoni, MD
Professor of Neurology and Chair of the MS Brain Health Steering Committee
On behalf of the MS Brain Health Steering Committee: Gavin Giovannoni, Peer Baneke, Helmut Butzkueven, Jodi Haartsen, Jeremy Hobart, Gisela Kobelt, Christoph Thalheim, Tony Traboulsee, Tim Vollmer and Tjalf Ziemssen
|
You forget to disclosed this presentarion you did for MerckMERCK TALK – Multiple Sclerosis 10:15 – 10:30 Scientific TheatrePresentationsSelective Immune Reconstitution Therapy in the Multiple Sclerosis treatment paradigmGavin Giovannoni, London, United Kingdomhttps://www.ean.org/lisbon2018/Scientific-Programme.3370.0.html
….And Roche….Patients' ChoiceHighlightRare DiseaseOverarching Theme Day 1 (16.06.2018)CDSCareer Development Session 108:30 – 10:00 Room OsloEtiological investigation of disease: case-control studiesCWCase-based Workshop 108:30 – 10:00 Room CbWEAN/EAPC: End-of-life care for neurological patientsFWFocused Workshop 108:30 – 10:00 Auditorium IIIBrain health in multiple sclerosis: a catalyst for a new approach to managementFWFocused Workshop 208:30 – 10:00 Auditorium VBiomarkers of neuromuscular disordersFWFocused Workshop 308:30 – 10:00 Room LisbonThe importance of brain network reorganisation in old age and for successful rehabilitation after strokeFWFocused Workshop 408:30 – 10:00 Room CopenhagenAbility to drive in neurological disordersFWFocused Workshop 508:30 – 10:00 Room BerlinOverarching theme: Familial amyloid polyneuropathy: phenotype, genetics, treatmentIaSInteractive Session 108:30 – 10:00 Auditorium VIEAN/ILAE-CEA: Classification of the epilepsies: Old wine in new skins?SpSSpecial Session 1208:30 – 10:00 Room Amsterdam25 Years of European Journal of Neurology – History, future and how to prepare your paper for publication3DS3-Days Satellite Session 110:00 – 10:30 Room 0.01CELGENE – The importance of real world evidence generation in Multiple SclerosisFPForum Programmes 110:15 – 10:30 Scientific TheatreMERCK TALK – Multiple SclerosisPresentationsSelective Immune Reconstitution Therapy in the Multiple Sclerosis treatment paradigmGavin Giovannoni, London, United KingdomSSymposium 110:30 – 12:30 Auditorium IEAN/MDS-ES: Tauopathies: pathophysiology, clinical features and experimental therapiesSSymposium 210:30 – 12:30 Auditorium VIDiagnosing genetic epilepsiesSSymposium 310:30 – 12:30 Auditorium VEAN/ESO: Cerebral small vessel disease – recent advances and clinical implicationsSSymposium 410:30 – 12:30 Auditorium VIIIEAN/EAPC: Palliative care and neurologySSymposium 910:30 – 12:30 Room BerlinEAN/ECTRIMS: Therapeutic challenges in progressive multiple sclerosisSTScientific Theatre 110:30 – 11:00European Pain FederationSTScientific Theatre 211:30 – 12:00EAN grants and other possibilitiesSTScientific Theatre 312:30 – 13:00eBook on neurological examinationSaSSatellite Symposium 0213:00 – 14:30 Auditorium VIROCHE – Redefining the management of relapsing Multiple Sclerosis & primary progressive Multiple SclerosisChairpersonGavin Giovannoni, London, United KingdomPresentationsWelcome and introductionGavin Giovannoni, London, United KingdomSuppressing disease activity and progression in relapsing Multiple Sclerosis and primary progressive Multiple SclerosisGavin Giovannoni, London, United KingdomOcrelizumab safety across relapsing Multiple Sclerosis and primary progressive Multiple SclerosisRalf Gold, Bochum, GermanyIncorporating Ocrelizumab into clinical practiceAaron Boster, Ohio, United StatesQuestions & AnswersAll faculty, ,ClosureGavin Giovannoni, London, United Kingdom